C=x Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding (x Is Chalcogen) Patents (Class 514/423)
  • Crystalline sodium atorvastatin
    Patent number: 8097734
    Abstract: Crystalline sodium atorvastatin, compositions containing the same and methods for the production thereof.
    Type: Grant
    Filed: August 15, 2006
    Date of Patent: January 17, 2012
    Assignees: Arrow International Limited, Zhejiang Neo-Dankong Pharmaceutical Co. Ltd.
    Inventors: Kailan Zhou, Hong Liu, Zhirong Chen, Huabin Hong, Yang Sun, Yunde Wang, Jiangchun Pan
  • N-SUBSTITUTED PYRROLIDINES
    Publication number: 20120010235
    Abstract: Compounds of formula and enantiomers and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control, amelioration or prevention of cancer.
    Type: Application
    Filed: June 30, 2011
    Publication date: January 12, 2012
    Inventors: Xin-Jie Chu, Qingjie Ding, Nan Jiang, Jin-Jun Liu, Tina Morgan Ross, Zhuming Zhang
  • NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT
    Publication number: 20120010264
    Abstract: The present invention provides a medicament for preventing and/or treating cognitive impairment, in particular Alzheimer's dementia, comprising 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propionic acid or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: March 26, 2010
    Publication date: January 12, 2012
    Applicant: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Hiroyoshi Kakuyama, Keiko Sakoda, Yoshihiro Iwamura, Atsushi Ikeda, Atsushi Tsuchida
  • Inhibitors of protein prenyltransferases
    Patent number: 8093274
    Abstract: The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of GGTase I. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: January 10, 2012
    Assignee: The Regents of the University of California
    Inventors: Fuyuhiko Tamanoi, Ohyun Kwon, Masaru Watanabe, Hannah Fiji
  • ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT
    Publication number: 20120004166
    Abstract: The invention relates to aryloxyalkylene-substituted hydroxyphenylhexynoic acid derivatives, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and A are each defined as specified, and physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.
    Type: Application
    Filed: July 5, 2011
    Publication date: January 5, 2012
    Applicant: SANOFI
    Inventors: Stefanie KEIL, Elisabeth DEFOSSA, Viktoria DIETRICH, Siegfried STENGELIN, Andreas HERLING, Guido HASCHKE, Thomas KLABUNDE
  • (2-ARYLOXYACETYLAMINO) PHENYLPROPIONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS
    Publication number: 20120004167
    Abstract: The invention relates to substituted (2-aryloxyacetylamino)phenylpropionic acid derivatives, and to the physiologically acceptable salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, R8, R9 and A are each defined as specified, and the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.
    Type: Application
    Filed: July 5, 2011
    Publication date: January 5, 2012
    Applicant: SANOFI
    Inventors: Elisabeth DEFOSSA, Stefanie KEIL, Viktoria DIETRICH, Siegfried STENGELIN, Andreas HERLING, Guido HASCHKE, Thomas KLABUNDE
  • HYDROXYPROLINE COMPOSITIONS AND USES THEREOF
    Publication number: 20120004157
    Abstract: The invention concerns novel use for Hydroxyproline in a pharmaceutical or dietary food or feed compositions for promoting growth e.g. of fish and/or for treating, ameliorating, or curing certain disorders including osteoporosis, psoriasis, enteritis and gingivitis.
    Type: Application
    Filed: June 6, 2008
    Publication date: January 5, 2012
    Applicant: Bergen Teknologioverforing AS
    Inventor: Anders Aksnes
  • Catechol-based derivatives for treating or preventing diabetics
    Patent number: 8088818
    Abstract: The present invention provides a catechol-based derivative and a pharmaceutical acceptable salt therefrom and a solvate therefrom. A pharmaceutical composition for preventing or treating diabetics and ischemics, comprising a catechol-based derivative of formula (I) and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: January 3, 2012
    Assignee: National Taiwan University
    Inventors: Yueh-Hsiung Kuo, Ming-Jai Su
  • Cyclohexyl-1, 4-diamine compounds
    Patent number: 8088763
    Abstract: Novel cyclohexyl-1,4-diamine compounds corresponding to formula I, processes for the production thereof, pharmaceutical compositions containing these compounds, methods of producing pharmaceutical compositions including these compounds and related methods of treating or inhibiting certain diseases or conditions.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: January 3, 2012
    Assignee: Gruenenthal GmbH
    Inventors: Corinna Sundermann, Bernd Sundermann
  • N-hydroxyamide derivatives possessing antibacterial activity
    Patent number: 8088804
    Abstract: Described herein are N-hydroxyamide antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical compositions compound of Formula (I): or a salt, solvate ti hydrate thereof, wherein A is (a) each indicates a point of attachment.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: January 3, 2012
    Assignee: Pfizer Inc.
    Inventors: Rakesh Kumar Jain, Mikhail Fedorovich Gordeev, Jason Gustaf Lewis, Charles Francavilla
  • METHOD AND COMPOSITIONS FOR THE TREATMENT AND DETECTION OF ENDOTHELIN-1 RELATED KIDNEY DISEASES
    Publication number: 20110319333
    Abstract: The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is also disclosed.
    Type: Application
    Filed: June 16, 2011
    Publication date: December 29, 2011
    Applicant: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Gale W. NEWMAN, Barbara A. JACOB-MUNGIN, Chamberlain OBIALO
  • Method and composition for treating heart failure
    Publication number: 20110319466
    Abstract: A method and composition for treating, preventing or ameliorating heart failure, cardiac hypertrophy, and/or myocardial dysfunction includes administering a therapeutically effective amount of a HDAC inhibitor, such as phenylbutyrate, in combination with an ACE inhibitor, such as captopril.
    Type: Application
    Filed: August 31, 2011
    Publication date: December 29, 2011
    Applicant: U.S. DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Wesley W. Brooks, Oscar H.L. Bing
  • Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
    Publication number: 20110319416
    Abstract: Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-E, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.
    Type: Application
    Filed: January 28, 2010
    Publication date: December 29, 2011
    Applicant: EMORY UNIVERSITY
    Inventors: Stephen F. Traynelis, Dennis C. Liotta, Cara Mosley, Timothy M. Acker, Sommer Zimmerman
  • CONTROLLED RELEASE PHARMACEUTICAL OR FOOD FORMULATION AND PROCESS FOR ITS PREPARATION
    Publication number: 20110318321
    Abstract: The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also relates to a slow release system represented by a mixture of a glycogen with a polysaccharide, and its use for the preparation of slow release pharmaceutical or food formulations.
    Type: Application
    Filed: January 8, 2010
    Publication date: December 29, 2011
    Applicant: AZIENDE CHIM.RIUN.ANG.FRANC.A.C.R.A.F. S.p.A.
    Inventors: Stefano Selva, Leonardo Marchitto, Giovanni Battista Ciottoli, Lorella Ragni, Vincenzo Russo, Elisa Liberati
  • Absorption Enhancement of Statins and Omega Fatty Acids
    Publication number: 20110319467
    Abstract: A composition and method to enhance absorption and bioavailability of Statin and Omega fatty acids consumed by humans and in an anhydrous base is presented.
    Type: Application
    Filed: June 21, 2011
    Publication date: December 29, 2011
    Inventor: Bhiku Patel
  • Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
    Patent number: 8084488
    Abstract: Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: December 27, 2011
    Assignee: Pfizer Inc.
    Inventors: Jason A. Leonard, Jonathan M. Miller
  • N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
    Patent number: 8084442
    Abstract: The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R101 and R102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: December 27, 2011
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Muneaki Kurimura, Shinichi Taira, Takahiro Tomoyasu, Nobuaki Ito, Kuninori Tai, Noriaki Takemura, Takayuki Matsuzaki, Yasuhiro Menjo, Shin Miyamura, Yohji Sakurai, Akihito Watanabe, Yasuyo Sakata, Takumi Masumoto, Kohei Akazawa, Haruhiko Sugino, Naoki Amada, Satoshi Ohashi, Tomoichi Shinohara, Hirofumi Sasaki, Chisako Morita, Junko Yamashita, Satoko Nakajima
  • CAVITY INDUCED ALLOSTERIC MODIFICATION OF INTERMOLECULAR INTERACTIONS AND METHODS OF IDENTIFYING COMPOUNDS THAT EFFECT THE SAME
    Publication number: 20110312920
    Abstract: Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed.
    Type: Application
    Filed: July 29, 2011
    Publication date: December 22, 2011
    Inventors: Ramachandran Murali, Mark I. Greene
  • ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS
    Publication number: 20110312890
    Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.
    Type: Application
    Filed: August 1, 2011
    Publication date: December 22, 2011
    Applicant: SIGNATURE R&D HOLDINGS, LLC
    Inventor: V. Ravi Chandran
  • CONTROLLED RELEASE COMPOSITIONS WITH REDUCED FOOD EFFECT
    Publication number: 20110311594
    Abstract: The present invention provides a controlled release pharmaceutical composition which exhibits reduced food effect.
    Type: Application
    Filed: June 21, 2011
    Publication date: December 22, 2011
    Inventors: Shou-Chiung Chen, Shao-Ming Lee, Chaur-Ming Jan
  • NARINGENIN COMPLEXES AND METHODS OF USE THEREOF
    Publication number: 20110312985
    Abstract: The invention relates to methods of treatment of hepatitis C, dyslipidemia, insulin resistance, and inflammation, with flavonoid-sugar complexes.
    Type: Application
    Filed: October 7, 2009
    Publication date: December 22, 2011
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Yaakov Nahmias, Martin L. Yarmush, Raymond T. Chung
  • NOVEL 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS
    Publication number: 20110311466
    Abstract: 4-(azacycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: Also described, are compositions including the same, processes for preparation thereof and uses thereof in pharmaceutical or cosmetic compositions to treat pigmentary disorders.
    Type: Application
    Filed: December 2, 2009
    Publication date: December 22, 2011
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Guy Boiteau, Karine Bouquet, Sandrine Talano, Corinne Millois Barbuis
  • GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
    Publication number: 20110312911
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: February 3, 2010
    Publication date: December 22, 2011
    Inventors: Roman Kats-Kagan, Christian P. Stevenson, Xibin Liao, Qinghong Fu, Emma R. Parmee, Songnian Lin
  • Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
    Patent number: 8080672
    Abstract: Provided is a crystal form of atorvastatin hemi-calcium and processes for its preparation.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: December 20, 2011
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Michael Pinchasov, Judith Aronhime, Zvika Doani
  • Compositions and methods for treatment of inflammatory bowel disease
    Patent number: 8080579
    Abstract: The present invention provides compositions and methods for treating inflammatory bowel disease. In particular, the present invention provides methods of therapeutically treating symptoms of inflammatory bowel disease using compositions comprising an angiotensin converting enzyme (ACE) inhibitor and polyethylene glycol.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: December 20, 2011
    Assignee: The Regents of The University of Michigan
    Inventors: Daniel H. Teitelbaum, Barbara E. Wildhaber, Hua Yang
  • FUNGICIDAL N-(PHENYLCYCLOALKYL)CARBOXAMIDE, N-(BENZYLCYCLOALKYL)CARBOXAMIDE AND THIOCARBOXAMIDE DERIVATIVES
    Publication number: 20110306646
    Abstract: The present invention relates to a N-(Phenylcycloalkyl)carboxamide or N-(Benzylcycloalkyl)carboxamide or its thiocarboxamide derivative of formula (I) wherein A represents a carbo-linked, unsaturated or partially saturated, substituted or non-substituted 5-membered heterocyclyl group, T represents an oxygen or a sulphur atom, B represents a non aromatic carbocycle that can be substituted by one to four C1-C8-alkyl groups, and X, Z1, Z2 and Z3 represent various substituents; their process of preparation; the preparation of intermediate compounds; their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.
    Type: Application
    Filed: February 16, 2010
    Publication date: December 15, 2011
    Inventors: Jurgen Benting, Peter Dahmen, Philippe Desbordes, Stephanie Gary, Marie-Claire Cournoyer, Philippe Rinolfi, Ulrike Wachendorff-Neumann
  • NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS
    Publication number: 20110306542
    Abstract: Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for use in structural analyses of the GLP-1 receptor. Methods of synthesis, methods of therapeutic and/or prophylactic use, and methods of use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor of such compounds are provided.
    Type: Application
    Filed: June 9, 2011
    Publication date: December 15, 2011
    Applicant: Receptos, Inc.
    Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Liming Huang, Junko Tamiya, Mark T. Griffith, Thomas Fowler, Andrew Novak, Michael Knaggs, Premji Meghani
  • BLOOD FLOW IMPROVING AGENT
    Publication number: 20110300239
    Abstract: An object of the present invention to obtain a blood flow improving agent composed of natural components, which increase activity or circulation of blood flow and accelerate decomposition, detoxication and elimination of toxic substances and supplement each other, and the production method thereof. The blood flow improving agent of the present invention is prepared by blending a nano-colloidized marine organic compound, more than one of trace elements containing minerals extracted from a mineral ore and nano-colloidized plant minerals and amino acids derived from a fuvic acid in nano-bubble water containing dissolved oxygen.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 8, 2011
    Inventor: Yukio Hasegawa
  • MALIGNANT NEOPLASM TREATMENT PROTOCOL
    Publication number: 20110300227
    Abstract: Methods, compositions, and strategies for the treatment of malignant neoplasms are presented herein. The treatment modalities are directed towards exploiting characteristics of cancer cells as well as correcting defective biochemical pathways and systems in the body.
    Type: Application
    Filed: May 20, 2011
    Publication date: December 8, 2011
    Applicant: NORTH TEXAS MEDICAL ASSOCIATES
    Inventor: Ivan E. Danhof
  • USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE
    Publication number: 20110301186
    Abstract: This invention is directed to methods and compositions for the treatment of cardiovascular disorders. Specifically, the invention is directed to compositions comprising vitamin E, statins and/or glutathione peroxidase mimetics; methods of treating diabetic patients expressing the Hp-2-2 haptoglobin genotype; a method of inhibiting or suppressing a cardiovascular disorder in a diabetic subject, treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype; and methods of treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype.
    Type: Application
    Filed: August 4, 2011
    Publication date: December 8, 2011
    Inventor: Andrew LEVY
  • Pyrrole Derivatives As Pharmaceutical Agents
    Publication number: 20110301128
    Abstract: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    Type: Application
    Filed: August 22, 2011
    Publication date: December 8, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Lynne Canne Bannen, Jeff Chen, Lisa Esther Dalrymple, Brenton T. Flatt, Timothy Patrick Forsyth, Xiao-Hui Gu, Morrison B. Mac, Larry W. Mann, Grace Mann, Richard Martin, Raju Mohan, Brett Murphy, Michael Charles Nyman, William C. Stevens, Tie-Lin Wang, Yong Wang, Jason H. Wu
  • Solid states of atorvastatin potassium
    Patent number: 8071638
    Abstract: Atorvastatin potassium crystalline Forms A, B, E, F, and G are provided. Also provided are methods of preparing atorvastatin potassium crystalline Forms A, B, E, F, and G. Atorvastatin potassium crystalline Forms A, B, E, F, and G may be used to prepare pharmaceutical compositions useful for the treatment of hypercholesterolemia or hyperlipidemia.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: December 6, 2011
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Yoav Kowalski, Ariel Mittelman, Sigalit Levi
  • Substituted aniline derivatives
    Patent number: 8071582
    Abstract: The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: December 6, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Andrew David Carr, Judi Charlotte Neuss, Michael Glen Orchard, David William Porter
  • HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS
    Publication number: 20110294793
    Abstract: The present invention provides compound of Formula (I): or a stereoisomer, tautomer, salt or solvate thereof, wherein the variables are defined herein. The compounds of formula (I) are inhibitors of Bcl-2 family antiapoptotic proteins, compositions containing the compounds and methods of treating diseases using the compounds.
    Type: Application
    Filed: June 8, 2009
    Publication date: December 1, 2011
    Inventors: kyoung S Kim, Robert M. Borzilleri, Zhen-Wei Cai, Kap-Sun Yeung
  • NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT
    Publication number: 20110294841
    Abstract: The invention provides novel omega-3 oil formulations of one or more statins. These formulations are readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oils as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. The invention also provides novel salts of one or more statins.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 1, 2011
    Inventors: Hector GUZMAN, Örn ALMARSSON, Julius REMENAR
  • DIRECTLY COMPRESSIBLE GRANULAR MICROCRYSTALLINE CELLULOSE BASED, EXCIPIENT, MANUFACTURING PROCESS AND USE THEREOF
    Publication number: 20110288146
    Abstract: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.
    Type: Application
    Filed: November 16, 2009
    Publication date: November 24, 2011
    Inventors: Nandu Deorkar, James Farina, Liliana Miinea, Sameer Ranadive
  • Benzamide derivative
    Patent number: 8063046
    Abstract: Compounds having high angiogenesis inhibiting activity useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, e.g.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: November 22, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroshi Koyano, Atsushi Suda, Kousuke Aso, Kihito Hada, Miyuki Asai, Masami Hasegawa, Yasuko Sato
  • Compositions and methods for regulating mammalian keratinous tissue
    Patent number: 8063097
    Abstract: Skin care compositions and methods for regulating the condition of mammalian keratinous tissue containing an effective amount of a dipalmitoyl hydroxyproline salt and a second skin care compound selected from hexamidine compounds, sugar amine compounds and their combination.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: November 22, 2011
    Assignee: The Procter & Gamble Company
    Inventors: Larry Richard Robinson, Paul Robert Tanner
  • Pyrrolidine ether derivatives as NK3 receptor antagonists
    Patent number: 8063075
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R?, Ar, m, n, and o are as defined herein. The invention also relates to pharmaceutical compositions containing compounds of formula I and methods for the manufacture of such compounds and compositions. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: November 22, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Philippe Jablonski, Kenichi Kawasaki, Henner Knust, Anja Limberg, Matthias Nettekoven, Hasane Ratni, Claus Riemer
  • Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof
    Publication number: 20110281928
    Abstract: The present invention relates to a process for the preparation of zofenopril and its pharmaceutically acceptable salts and a pharmaceutical composition thereof. The present invention also provides structurally novel compounds, which are useful intermediates in the synthesis of zofenopril.
    Type: Application
    Filed: January 24, 2010
    Publication date: November 17, 2011
    Applicant: GLENMARK GENERICS LTD
    Inventors: Mubeen Ahmed Khan, Roop Singh Yadav, Nikhil Rasiklal Trivedi, Sachin Mahedo Lad
  • Inhibitors of IAP
    Publication number: 20110281875
    Abstract: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).
    Type: Application
    Filed: July 8, 2011
    Publication date: November 17, 2011
    Inventors: Mark G. PALERMO, Sushil Kumar SHARMA, Christopher STRAUB, Run-Ming WANG, Leigh ZAWEL, Yanlin ZHANG, Zhuoliang CHEN, Yaping WANG, Fan YANG, Wojciech WRONA, Gang LIU, Mark G. CHAREST, Feng HE
  • Combination therapy for the prevention of statin induced diabetes
    Publication number: 20110275649
    Abstract: Novel combinations comprising HMG CoA reductase inhibitors, or statins, with partial fatty acid oxidation inhibitors (pFOXi), and methods for their use, are disclosed. These combinations are useful in preventing or reducing the risk of developing diabetes which results from therapy with a statin.
    Type: Application
    Filed: May 3, 2011
    Publication date: November 10, 2011
    Applicant: Palmetto Pharmaceuticals LLC
    Inventor: Wayne H. Kaesemeyer
  • Preparation of 3-Pyrrole Substituted 2-Indolinone Derivatives
    Publication number: 20110275689
    Abstract: The present invention relates to novel intermediates and further to the use of said intermediates in processes for the preparation of indolinone derivatives, in particular 3-pyrrole substituted 2-indolinones having amide moieties on the pyrrole ring. Such compounds are useful in die treatment of abnormal cell growth, such as cancer, in mammals.
    Type: Application
    Filed: July 1, 2009
    Publication date: November 10, 2011
    Applicant: GENERICS [UK] LIMITED
    Inventors: Abhay Gaitonde, Bharati Choudhari, Prakash Bansode, Sunanda Phadtare
  • Benzophenone derivatives useful for inhibiting formation of microtubule
    Patent number: 8053439
    Abstract: Disclosed herein are novel benzophenone derivatives represented by formula I, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, a pharmacological composition containing the same, and a use of the composition as therapeutic drugs. The benzophenone derivatives have an inhibition activity of microtubule formation and can be used to treat a normal proliferative state of a malignant tumor by killing the actively proliferating cells.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: November 8, 2011
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Nam-Song Choi, Young-Mi Kim, Young-Hoon Kim, Jae-Kwang Lee, In-Taek Lim, Ho-Jin Choi, Hyun-Mo Yang, Seung-Kee Moon, Soo-Jin Kim, Hyun-Jung Yu, Jae-Su Shin, Young-Min Kwon, Sung-Sook Lee, Soon-Kil Ahn, Sun-Ju Kong
  • Attractants for insects such as flies
    Patent number: 8053464
    Abstract: A composition containing at least two members of the group consisting of propionic acid, benzoic acid, 2,6-dimethoxyphenol, 2-acetylpyrrole, 2-hydroxy-3-methyl-2-cyclopentanone, 2-methyltetrahydrofuran-3-one, and 3-methylbutanal; and water, and optionally a carrier or carrier material. The composition is useful for attracting insects (e.g., flies). A method for attracting insects (e.g., flies) involving treating an object or area with an insect attracting effective amount of the composition described herein.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: November 8, 2011
    Assignees: The United States of America as represented by the Secretary of Agriculture, University of Florida Research Foundation Incorporated
    Inventors: Brian P. Quinn, David A. Carlson, Christopher J. Geden, Ulrich R. Bernier, Matthew M. Booth, Jerome A. Hogsette, Jr.
  • Bicycloester derivative
    Patent number: 8053465
    Abstract: Summary Novel bicycloester derivatives and pharmaceutically acceptable salts thereof have high DPP-IV inhibitory activity. Solving Means The novel bicycloester derivatives are represented by the general formula (1): Pharmaceutically acceptable salts thereof are also included (Example: (2S,4S)-1-[[(N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)).
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: November 8, 2011
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Yasumichi Fukuda, Yoshikazu Asahina, Kohei Ohata, Kazuya Yokota, Koji Murakami, Toshiyuki Matsui
  • COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE, AND INFLAMMATORY DISEASES
    Publication number: 20110269755
    Abstract: The disclosure provides compositions and methods for the treatment of vascular, autoimmune, and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor.
    Type: Application
    Filed: December 9, 2010
    Publication date: November 3, 2011
    Applicant: Aspreva International Ltd.
    Inventors: Michael HAYDEN, Noel Hall
  • GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20110269735
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Application
    Filed: April 13, 2011
    Publication date: November 3, 2011
    Applicant: CELERA CORPORATION
    Inventors: Dov SHIFFMAN, James J. DEVLIN, May LUKE, David A. ROSS
  • PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS
    Publication number: 20110269722
    Abstract: The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.
    Type: Application
    Filed: December 23, 2010
    Publication date: November 3, 2011
    Inventor: Apparao Satyam
  • CHEWABLE GELLED EMULSIONS
    Publication number: 20110268770
    Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a statin within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, one or both of the oil phase and the water phase whereof comprises a physiologically tolerable omega-3 acid ester.
    Type: Application
    Filed: October 8, 2009
    Publication date: November 3, 2011
    Applicant: PROBIO ASA
    Inventors: Tore Seternes, Kurt Ingar Draget, Ingvild Johanne Haug